CY1115519T1 - Φαρμακευτικο παρασκευασμα που περιεχει λιπαση βακτηριακης προελευσης - Google Patents

Φαρμακευτικο παρασκευασμα που περιεχει λιπαση βακτηριακης προελευσης

Info

Publication number
CY1115519T1
CY1115519T1 CY20141100699T CY141100699T CY1115519T1 CY 1115519 T1 CY1115519 T1 CY 1115519T1 CY 20141100699 T CY20141100699 T CY 20141100699T CY 141100699 T CY141100699 T CY 141100699T CY 1115519 T1 CY1115519 T1 CY 1115519T1
Authority
CY
Cyprus
Prior art keywords
pharmaceutical preparation
preparation containing
bacterial origin
containing bacterial
origin lipase
Prior art date
Application number
CY20141100699T
Other languages
English (en)
Inventor
Manfred Kurfürst
Rainer Friedel
Olaf Friedrich
Silke Hüttler
Christian Rämsch
Original Assignee
Nordmark Arzneimittel Gmbh & Co. Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nordmark Arzneimittel Gmbh & Co. Kg filed Critical Nordmark Arzneimittel Gmbh & Co. Kg
Publication of CY1115519T1 publication Critical patent/CY1115519T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Το φαρμακευτικό παρασκεύασμα που προορίζεται για τη θεραπεία της παγκρεατικής ανεπάρκειας περιλαμβάνει μια ρευστή μορφή χορήγησης των ενζύμων.
CY20141100699T 2009-01-29 2014-09-02 Φαρμακευτικο παρασκευασμα που περιεχει λιπαση βακτηριακης προελευσης CY1115519T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09776346.0A EP2391382B1 (de) 2009-01-29 2009-01-29 Pharmazeutisches präparat enthaltend lipase bakteriellen ursprungs
PCT/EP2009/000566 WO2010085975A1 (de) 2009-01-29 2009-01-29 Pharmazeutisches präparat enthaltend lipase bakteriellen ursprungs

Publications (1)

Publication Number Publication Date
CY1115519T1 true CY1115519T1 (el) 2017-01-04

Family

ID=41091375

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20141100699T CY1115519T1 (el) 2009-01-29 2014-09-02 Φαρμακευτικο παρασκευασμα που περιεχει λιπαση βακτηριακης προελευσης

Country Status (13)

Country Link
US (2) US20110293590A1 (el)
EP (2) EP2786761A1 (el)
JP (1) JP5970189B2 (el)
CN (1) CN102231988A (el)
BR (1) BRPI0922653B8 (el)
CY (1) CY1115519T1 (el)
DK (1) DK2391382T3 (el)
ES (1) ES2488407T3 (el)
HR (1) HRP20140715T1 (el)
PL (1) PL2391382T3 (el)
PT (1) PT2391382E (el)
SI (1) SI2391382T1 (el)
WO (1) WO2010085975A1 (el)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2165717A1 (de) 2008-08-27 2010-03-24 Nordmark Arzneimittel GmbH & Co.KG Verfahren zur Verringerung der viralen und mikrobiellen Belastung feststoffhaltiger biologischer Extrakte
PL2295039T5 (pl) 2009-08-28 2023-02-27 Nordmark Pharma Gmbh Sposób wytwarzania granulek zawierających pankreatynę, w szczególności mikrogranulek zawierających pankreatynę, oraz wytworzone tym sposobem granulki zawierające pankreatynę
EP2489349B1 (de) 2011-02-17 2014-05-28 Nordmark Arzneimittel GmbH & Co.KG Pankreatin-Pellets, insbesondere Pankreatin-Mikropellets, und Verfahren zu deren Herstellung
US8268305B1 (en) 2011-09-23 2012-09-18 Bio-Cat, Inc. Method and compositions to reduce serum levels of triacylglycerides in human beings using a fungal lipase
WO2013146529A1 (ja) * 2012-03-28 2013-10-03 不二製油株式会社 ランダムエステル交換油脂の製造方法
DE102015114857A1 (de) 2015-09-04 2017-03-09 Nordmark Arzneimittel Gmbh & Co. Kg Getränk, enthaltend eine pharmazeutische Zusammensetzung
DE102017104501A1 (de) 2017-03-03 2018-09-06 Nordmark Arzneimittel Gmbh & Co. Kg Pharmazeutische Zusammensetzung umfassend einen Träger und einen Überzug enthaltend wenigstens eine Lipase
DE102017104480A1 (de) * 2017-03-03 2018-09-06 Nordmark Arzneimittel Gmbh & Co. Kg Wässrige Lösung von Burlulipase umfassend Kalziumionen
DE102017104482A1 (de) * 2017-03-03 2018-09-06 Nordmark Arzneimittel Gmbh & Co. Kg Pharmazeutische Zusammensetzung umfassend Pankreatin und einen lipasehaltigen Überzug
DE102017104472A1 (de) * 2017-03-03 2018-09-06 Nordmark Arzneimittel Gmbh & Co. Kg Schmelztablette enthaltend Burlulipase und daraus hergestellte pharmazeutische Zusammensetzung
MX2022002473A (es) 2019-08-30 2022-08-02 Codexis Inc Variantes de lipasa modificadas geneticamente.

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2189948A (en) 1938-10-31 1940-02-13 Griffith Laboratories Sterilization of pancreatin
DE2923279C2 (de) 1979-06-08 1987-07-09 Kali-Chemie Pharma Gmbh, 3000 Hannover Verfahren zur Herstellung von Pankreatin-Pellets und diese enthaltende Arzneimittel
US5063160A (en) * 1989-03-16 1991-11-05 Olin Corporation Identification, characterization, and method of production of a novel microbial lipase
PH30058A (en) 1989-11-24 1996-11-08 Biochemie Gmbh Pancreation preparations
DK173590D0 (da) 1990-06-06 1990-07-19 Novo Nordisk As Rekombinante terapeutiske lipaser
WO1993000924A1 (de) * 1991-07-01 1993-01-21 Basf Aktiengesellschaft Verwendung von lipasen zur herstellung von arzneimitteln
DE4227385A1 (de) 1992-08-19 1994-02-24 Kali Chemie Pharma Gmbh Pankreatinmikropellets
JPH08143469A (ja) * 1994-11-14 1996-06-04 Amano Pharmaceut Co Ltd 膵外分泌機能不全症治療剤
DE19724845A1 (de) 1996-08-28 1998-03-05 Solvay Pharm Gmbh Verwendung von komplexen Lipiden als stabilisierende Zusätze zu pharmazeutischen Zubereitungen von Verdauungsenzymgemischen
US6270723B1 (en) 1998-06-15 2001-08-07 Bbi Bioseq, Inc. Rapid cryobaric sterilization and vaccine preparation
US20010046493A1 (en) 2000-02-24 2001-11-29 Alex Margolin Lipase-containing composition and methods of use thereof
DE60104837T2 (de) 2000-04-06 2005-09-01 The Hannah Research Institute Protein-stabilisierte emulsionen
AT502588B1 (de) * 2002-11-26 2010-05-15 Brenner Franz Papaya-mus
EP1486415A1 (en) 2003-06-12 2004-12-15 SSP Technology A/S Wind turbine blade and method of manufacturing a blade root
US6908789B1 (en) 2003-12-15 2005-06-21 Intel Corporation Method of making a microelectronic assembly
ES2314646T3 (es) * 2004-03-22 2009-03-16 Solvay Pharmaceuticals Gmbh Composiciones farmaceuticas por via de productos que contienen lipasa , en particular de pancreatina, que contienen tensioactivos.
SI1809320T1 (sl) 2004-10-14 2010-11-30 Cystic Fibrosis Foundation Therapeutics Inc Sestavki ki vsebujejo lipazo proteazo in amilazo za zdravljenje pankreasne insuficience
DE102004056340B4 (de) 2004-11-22 2010-11-18 Repower Systems Ag Vorrichtung und Verfahren zur Montage und/oder Demontage eines Bauteils einer Windkraftanlage
DE102005014868A1 (de) 2005-03-30 2006-10-05 Repower Systems Ag Offshore-Windenergieanlage mit rutschfesten Füßen
US11266607B2 (en) 2005-08-15 2022-03-08 AbbVie Pharmaceuticals GmbH Process for the manufacture and use of pancreatin micropellet cores
DE102006021982C5 (de) 2006-05-10 2010-10-07 Repower Systems Ag Gestaffelt abschaltbarer Windpark
AU2008218595B2 (en) * 2007-02-20 2012-05-24 Allergan Therapeutics LLC Stable digestive enzyme compositions
DE102007014863A1 (de) 2007-03-26 2008-10-02 Repower Systems Ag Verfahren zum Betreiben einer Windenergieanlage
AU2008239737A1 (en) 2007-04-13 2008-10-23 Beth Israel Deaconess Medical Center, Inc. Novel nutritional food products for improved digestion and intestinal absorption
DE102008012664A1 (de) 2008-01-30 2009-08-06 Repower Systems Ag Windenergieanlage und ein Turm oder Turmsegment und eine Türzarge dafür
EP2165717A1 (de) 2008-08-27 2010-03-24 Nordmark Arzneimittel GmbH & Co.KG Verfahren zur Verringerung der viralen und mikrobiellen Belastung feststoffhaltiger biologischer Extrakte
PL2295039T5 (pl) 2009-08-28 2023-02-27 Nordmark Pharma Gmbh Sposób wytwarzania granulek zawierających pankreatynę, w szczególności mikrogranulek zawierających pankreatynę, oraz wytworzone tym sposobem granulki zawierające pankreatynę
EP2489349B1 (de) 2011-02-17 2014-05-28 Nordmark Arzneimittel GmbH & Co.KG Pankreatin-Pellets, insbesondere Pankreatin-Mikropellets, und Verfahren zu deren Herstellung

Also Published As

Publication number Publication date
JP5970189B2 (ja) 2016-08-17
BRPI0922653A2 (pt) 2016-01-05
US20110293590A1 (en) 2011-12-01
PT2391382E (pt) 2014-08-22
DK2391382T3 (da) 2014-08-25
PL2391382T3 (pl) 2014-11-28
HRP20140715T1 (hr) 2014-09-26
BRPI0922653B8 (pt) 2021-05-25
SI2391382T1 (sl) 2014-10-30
WO2010085975A1 (de) 2010-08-05
EP2391382A1 (de) 2011-12-07
US10596235B2 (en) 2020-03-24
US20160287679A1 (en) 2016-10-06
CN102231988A (zh) 2011-11-02
EP2786761A1 (de) 2014-10-08
EP2391382B1 (de) 2014-06-04
JP2012516289A (ja) 2012-07-19
BRPI0922653B1 (pt) 2021-04-13
ES2488407T3 (es) 2014-08-27

Similar Documents

Publication Publication Date Title
EA201200559A1 (ru) Способы назначения терапии пирфенидоном
BR112012015721A2 (pt) modificação covalente de proteínas dirigida por ligante
BR112012018761A2 (pt) estruturas para prevenir fixação de microorganismos
CR20140321A (es) Sistema de administracion transdermica que contiene buprenofina
IT1398927B1 (it) Espressione batterica di un gene artificiale per la produzione di crm197 e derivati.
CL2015000812A1 (es) Una capsula de bebida que comprende un cuerpo de capsula, una pared para inyeccion, una division, un medio para ruptura, una cantidad de un ingrediente de bebida, un soporte de sellado con una superficie de sellado; sistema de bebidas; y metodo de preparacion.
EP2398459A4 (en) TRANSDERMAL RELEASE OF DICLOFENAC, CARBAMAZEPINE AND BENZYDAMINE
BRPI0922653B8 (pt) uso de uma lipase bacteriana do tipo pseudomonas em solução aquosa
MX385616B (es) Inhibidores de cdk
PH12014500956A1 (en) Pak inhibitor for the treatment of fragile x syndrome
DK2464343T3 (da) System til indgivelse af oftalmisk medicin indeholdende phospholipid og kolesterol
CO6640205A2 (es) Microorganismos y metodos para la biosintesis de p-toluato y tereftalato
CL2015003580A1 (es) Conjugados de suministro de polinucleotidos in vivo que tienen acoplamientos sensibles a enzima.
MY200738A (en) Pyrazole magl inhibitors
UA107476C2 (uk) Фармацевтична субстанція на основі мітохондріально адресованих антиоксидантів
BR112012029985A2 (pt) métodos de determinação de rotatividade beta-amiloide no sangue.
CL2012003523A1 (es) Método para la preparación de una composición farmacéutica que contiene un portador de oxígeno termoestable; composicion farmaceutica que contiene un portador de oxigeno altamente purificado y termoestable.
UA111475C2 (uk) Способи лікування із застосуванням ліпідних сполук
MX336787B (es) Microorganismos deseñados geneticamente que comprenden 4-hidroxibenzoil-coa tioesterasas y metodos de uso de los mismos para producir acidos grasos libes y derivados de acidos grasos.
CL2011002649A1 (es) Uso de un aerosol que comprende levofloxacina u ofloxacina para preparar un medicamento util para el tratamiento de una infeccion bacteriana pulmonar.
BR112013016306A2 (pt) preparação enzimática da fermentação de koji.
WO2010099510A3 (en) Amino acid-based compounds, their methods of use, and methods of screening
EP2547203A4 (en) CCR5 MODULATORS TO TREAT HIV
MX2011006721A (es) Formulacion farmaceutica de fenofibrato nanonizado.
AR087586A1 (es) Sistema enzimatico